PriceTargets.com logo

MiNK Therapeutics - INKT Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $35.00
  • Forecasted Upside: 183.40%
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 1 Buy Ratings
  • 1 Strong Buy Ratings
$12.35 As of 12/4/2025 04:59 PM ET
▲ +1.42 (12.99%)

This chart shows the closing price for INKT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New MiNK Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INKT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INKT

Analyst Price Target is $35.00
▲ +183.40% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for MiNK Therapeutics in the last 3 months. The average price target is $35.00, with a high forecast of $35.00 and a low forecast of $35.00. The average price target represents a 183.40% upside from the last price of $12.35.

This chart shows the closing price for INKT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 5 contributing investment analysts is to hold stock in MiNK Therapeutics. This rating changed within the last month from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
9/5/2025
  • 1 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 1 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 1 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/20/2025Zacks ResearchUpgradeStrong Sell ➝ Hold
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
8/18/2025Zacks ResearchDowngradeHold ➝ Strong Sell
8/15/2025HC WainwrightUpgradeNeutral ➝ Buy$35.00 ➝ $35.00
7/18/2025B. RileyUpgradeStrong-Buy
7/15/2025HC WainwrightDowngradeBuy ➝ Neutral$35.00
7/11/2025William BlairDowngradeOutperform ➝ Market Perform
3/18/2025HC WainwrightReiterated RatingBuy ➝ Buy$35.00 ➝ $35.00
2/25/2025HC WainwrightBoost TargetBuy ➝ Buy$9.00 ➝ $35.00
11/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$90.00 ➝ $90.00
11/15/2024Robert W. BairdLower TargetOutperform ➝ Outperform$80.00 ➝ $40.00
10/9/2024HC WainwrightReiterated RatingBuy ➝ Buy$90.00 ➝ $90.00
8/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$90.00 ➝ $90.00
5/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$90.00
3/21/2024HC WainwrightLower TargetBuy ➝ Buy$100.00 ➝ $90.00
8/10/2023HC WainwrightReiterated RatingBuy ➝ Buy$100.00
5/12/2023B. RileyReiterated RatingBuy
4/19/2023HC WainwrightReiterated RatingBuy$70.00
3/22/2023Evercore ISILower TargetOutperform$40.00 ➝ $30.00
3/22/2023HC WainwrightReiterated RatingBuy$70.00
8/10/2022HC WainwrightInitiated CoverageBuy$70.00
5/11/2022B. RileyLower Target$100.00 ➝ $70.00
1/24/2022B. RileyLower TargetBuy$240.00 ➝ $100.00
11/9/2021Evercore ISIInitiated CoverageOutperform$300.00
11/9/2021William BlairInitiated CoverageOutperform
11/9/2021B. RileyInitiated CoverageBuy$240.00
11/9/2021Robert W. BairdInitiated CoverageOutperform$260.00
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.58 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 0 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 6 very positive mentions
  • 18 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
8/6/2025
  • 5 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/5/2025
  • 4 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/4/2025
  • 6 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 6 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

MiNK Therapeutics logo
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Read More

Today's Range

Now: $12.35
Low: $10.51
High: $12.50

50 Day Range

MA: $13.28
Low: $10.56
High: $15.46

52 Week Range

Now: $12.35
Low: $4.56
High: $76.00

Volume

36,478 shs

Average Volume

17,416 shs

Market Capitalization

$57.92 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.35

Frequently Asked Questions

What sell-side analysts currently cover shares of MiNK Therapeutics?

The following equities research analysts have issued research reports on MiNK Therapeutics in the last twelve months: B. Riley, HC Wainwright, Wall Street Zen, Weiss Ratings, William Blair, and Zacks Research.
View the latest analyst ratings for INKT.

What is the current price target for MiNK Therapeutics?

0 Wall Street analysts have set twelve-month price targets for MiNK Therapeutics in the last year. Their average twelve-month price target is $35.00, suggesting a possible upside of 183.4%. HC Wainwright has the highest price target set, predicting INKT will reach $35.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $35.00 for MiNK Therapeutics in the next year.
View the latest price targets for INKT.

What is the current consensus analyst rating for MiNK Therapeutics?

MiNK Therapeutics currently has 1 sell rating, 2 hold ratings, 1 buy rating and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in INKT, but not buy more shares or sell existing shares.
View the latest ratings for INKT.

What other companies compete with MiNK Therapeutics?

Other companies that are similar to MiNK Therapeutics include Future FinTech Group, Corbus Pharmaceuticals, MediWound, Neoleukin Therapeutics and VistaGen Therapeutics. Learn More about companies similar to MiNK Therapeutics.

How do I contact MiNK Therapeutics' investor relations team?

The company's listed phone number is 212-994-8250 and its investor relations email address is [email protected]. The official website for MiNK Therapeutics is www.minktherapeutics.com. Learn More about contacing MiNK Therapeutics investor relations.